Acalisib

DB15407InvestigationalSmall molecule

Acalisib is under investigation in clinical trial NCT01705847 (A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies).

Mechanism: Pharmacologically active on Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
Curator reviewed
Formula / weight: C₂₁H₁₆FN₇O · 401.405 g/mol (avg)
Code names: CAL-120

Resolves to

Compound

Structure

InChIKeyDOCINCLJNAXZQF-LBPRGKRZSA-NSMILESC[C@H](NC1=NC=NC2=C1NC=N2)C1=NC2=C(C=C(F)C=C2)C(=O)N1C1=CC=CC=C1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Acalisib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.